All stock lists
Sanofi (NASDAQ:SNY)
FR · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - General
43.13+0.89 (+2.11%)
Market cap
$103B
Insider Score
Health Score
Analyst consensus
Listed since
Jul 1, 2002
Website
Insider Score
/ 99
SNY Insider Score
Sanofi has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
Unlock SNY’s Insider ScoreFinancial Health Score
Sound
From SNY’s reported statements · Q2 2026 (trailing 12 months)
Profitability14 / 20
Profitable, but on a thin margin.
- Revenue
- $48.92B
- Net income
- $3.96B
- Net margin
- 8.1%
Leverage14 / 20
A manageable debt load.
- Total debt
- $23.58B
- Cash
- $6.35B
- Net debt / EBITDA
- 1.17x
Liquidity6 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $31.52B
- Current liabilities
- $31.93B
- Current ratio
- 0.99
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $14.29B
- Free cash flow
- $11.77B
- FCF margin
- 24.1%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 2393.2M
- Share growth (1y)
- -3.0%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
SNY Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 12.30 B | 11.24 B | 12.21 B | 13.17 B | 10.73 B | 10.61 B |
| Revenue Growth (YoY) | 14.58 % | 6.02 % | 59.94 % | -6.97 % | -5.67 % | 9.05 % |
| Cost of Revenue | 3.02 B | 3.14 B | 3.63 B | 3.41 B | 2.99 B | 2.89 B |
| Gross Profit | 9.28 B | 8.11 B | 8.57 B | 9.76 B | 7.74 B | 7.72 B |
| SG&A Expense | 2.63 B | 2.49 B | 2.40 B | 2.29 B | 2.63 B | 2.39 B |
| R&D Expense | 2.23 B | 1.75 B | 2.29 B | 1.83 B | 1.91 B | 1.81 B |
| Operating Expenses | 6.90 B | 5.84 B | 9.61 B | 6.13 B | 6.27 B | 5.48 B |
| Operating Income | 2.38 B | 2.27 B | -1.04 B | 3.62 B | 1.47 B | 2.23 B |
| Pretax Income | 828.00 M | 2.01 B | -1.16 B | 3.51 B | 1.47 B | 2.20 B |
| Tax Provision | 451.00 M | 420.00 M | -348.00 M | 680.00 M | 230.00 M | 481.00 M |
| Net Income | 343.00 M | 1.61 B | -801.00 M | 2.80 B | 3.94 B | 1.87 B |
| EPS (Basic) | 0.14 | 0.67 | -1.48 | 1.15 | 1.60 | 0.76 |
| EPS (Diluted) | 0.14 | 0.67 | -1.46 | 1.14 | 1.60 | 0.76 |
| Shares Outstanding | 2.39 B | 2.41 B | 2.44 B | 2.44 B | 2.47 B | 2.47 B |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.